Molecular Cancer Therapeutics Funding
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Vol. 1, 539-544, May 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

The Biological Sequelae of Stromal Cell-derived Factor-1{alpha} in Multiple Myeloma1

Teru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, Klaus Podar, Masaharu Akiyama, Deepak Gupta, Paul Richardson, Nikhil Munshi and Kenneth C. Anderson2

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115

Stromal cell-derived factor (SDF)-1{alpha} mediates migration of normal hematopoietic stem cells, but its role in hematological malignancies is undefined. In this study, we detected SDF-1{alpha} in bone marrow (BM) plasma from 10 patients with MM (multiple myeloma; 2.6 ± 1.5 ng/ml) and BM stromal cell culture supernatants from 5 patients with MM (0.6 ± 0.2 ng/ml). We show that SDF-1{alpha} promotes proliferation, induces migration, and protects against dexamethasone-induced apoptosis in MM cells, but these effects are only modest. In MM cell lines and patient MM cells, SDF-1{alpha} induces phosphorylation of p42/44 mitogen-activated protein kinase, as well as Akt and its downstream target Bad, and also activates nuclear factor-{kappa}B. In the BM milieu, SDF-1{alpha} up-regulates secretion of interleukin 6 and vascular endothelial growth factor in BM stromal cells, which promote tumor cell growth, survival, and migration. These data demonstrate that SDF-1{alpha} promotes growth, migration and drug resistance of MM cells in the BM microenvironment, but these effects are only modest, SDF-1{alpha} therefore does not represent a target for novel therapeutics in this disease.




This article has been cited by other articles:


Home page
BloodHome page
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells
Blood, April 1, 2008; 111(7): 3364 - 3372.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Blood, December 15, 2007; 110(13): 4417 - 4426.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
Blood, April 1, 2007; 109(7): 2708 - 2717.
[Abstract] [Full Text] [PDF]


Home page
ASH-SAPHome page
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. K. Martin, A. L. Dewar, A. N. Farrugia, N. Horvath, S. Gronthos, L. B. To, and A. C.W. Zannettino
Tumor Angiogenesis Is Associated with Plasma Levels of Stromal-Derived Factor-1{alpha} in Patients with Multiple Myeloma
Clin. Cancer Res., December 1, 2006; 12(23): 6973 - 6977.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood, May 15, 2006; 107(10): 4053 - 4062.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Nishio, T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. C. Reed, N. J. Zvaifler, and T. J. Kipps
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1{alpha}
Blood, August 1, 2005; 106(3): 1012 - 1020.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
Blood, July 15, 2005; 106(2): 706 - 712.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. C.W. Zannettino, A. N. Farrugia, A. Kortesidis, J. Manavis, L. B. To, S. K. Martin, P. Diamond, H. Tamamura, T. Lapidot, N. Fujii, et al.
Elevated Serum Levels of Stromal-Derived Factor-1{alpha} Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients
Cancer Res., March 1, 2005; 65(5): 1700 - 1709.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello
Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors
Cancer Res., March 1, 2005; 65(5): 2026 - 2034.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
PNAS, January 13, 2004; 101(2): 540 - 545.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
Y. Gazitt and C. Akay
Mobilization of Myeloma Cells Involves SDF-1/CXCR4 Signaling and Downregulation of VLA-4
Stem Cells, January 1, 2004; 22(1): 65 - 73.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman, D. Chauhan, and K. C. Anderson
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
Blood, January 15, 2003; 101(2): 703 - 705.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.